Global pharma major Lupin Limited (Lupin) has announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), rufinamide tablets USP, 100 mg, 200 mg, and 400 mg, to market a generic equivalent of Banzel tablets, 100 mg, 200 mg, and 400 mg, of Eisai Inc.
The product will be manufactured at Lupin
